<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117245</url>
  </required_header>
  <id_info>
    <org_study_id>265-105</org_study_id>
    <nct_id>NCT02117245</nct_id>
  </id_info>
  <brief_title>Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers</brief_title>
  <official_title>Phase I Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the bioavailability of the MGCD265 formulation&#xD;
      following oral administration under fed conditions (Treatment-1) as compared to fasting&#xD;
      conditions (Treatment-2) in healthy male and female volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to assess the bioavailability of the MGCD265 formulation following&#xD;
      oral administration under fed conditions (Treatment-1) as compared to fasting conditions&#xD;
      (Treatment-2) in healthy male and female volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma concentration (Cmax) of MGCD265.</measure>
    <time_frame>26 days</time_frame>
    <description>Bioavailability of study drug under fed conditions compared to fasting conditions in healthy male and female volunteers.</description>
  </primary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Pharmacodynamic analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy male and female volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female volunteer&#xD;
&#xD;
          2. Volunteer age of 40 to 65 years&#xD;
&#xD;
          3. Females of childbearing potential using a stable contraceptive method at least 14 days&#xD;
             prior to screening and willing to use acceptable birth control methods from 7 days&#xD;
             prior to first dose until 30 days after last dose of study drug:&#xD;
&#xD;
          4. Female volunteers will be considered of non childbearing potential and eligible if:&#xD;
&#xD;
               -  Amenorrhea for at least 1 year;&#xD;
&#xD;
               -  Hysterectomy;&#xD;
&#xD;
               -  Bilateral oophorectomy at least 6 weeks prior to first dose;&#xD;
&#xD;
               -  Bilateral tubal ligation at least 6 months prior to first dose;&#xD;
&#xD;
               -  Hysteroscopic sterilization.&#xD;
&#xD;
          5. Male volunteers who agree to be abstinent or use acceptable contraception methods in&#xD;
             collaboration with their female partner from the time of taking the first dose until&#xD;
             90 days after the last dose of study drug:&#xD;
&#xD;
             â€¢ Male volunteers who also agree to not donate sperm from the time of taking the first&#xD;
             dose until 90 days after the last dose.&#xD;
&#xD;
          6. Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00&#xD;
             kg/m2&#xD;
&#xD;
          7. Non- or ex smokers for at least 6 months.&#xD;
&#xD;
          8. Availability for the entire study period&#xD;
&#xD;
          9. Motivated volunteer and absence of intellectual problems likely to limit the validity&#xD;
             of consent to participate in the study or the compliance with protocol requirements&#xD;
&#xD;
         10. Clinical laboratory values within the laboratory's stated normal range; or they must&#xD;
             be without any clinical significance&#xD;
&#xD;
         11. Have no clinically significant diseases captured in medical history or evidence of&#xD;
             clinically significant findings on physical examination and/or clinical laboratory&#xD;
             evaluations&#xD;
&#xD;
         12. Willingness to adhere to protocol requirements&#xD;
&#xD;
        The informed consent form must be signed by all volunteers, prior to participation in the&#xD;
        study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or are lactating&#xD;
&#xD;
          2. History of significant hypersensitivity reactions to any substance or drug&#xD;
&#xD;
          3. History or presence of significant gastrointestinal, liver or kidney disease, or any&#xD;
             other conditions known to interfere with absorption, distribution, metabolism or&#xD;
             excretion of drugs&#xD;
&#xD;
          4. Seated blood pressure higher than and equal to 140/90 mmHg at screening&#xD;
&#xD;
          5. Seated blood pressure higher than and equal to 140/90 mmHg before drug administration&#xD;
&#xD;
          6. History or predisposition to cardiovascular illness&#xD;
&#xD;
          7. History or predisposition to thrombotic or hemorrhagic events, bleeding diathesis or&#xD;
             coagulopathy, gastrointestinal or other conditions with risk of perforation, presence&#xD;
             of a non-healing wound, ulcer or fracture&#xD;
&#xD;
          8. Presence of significant pulmonary, hematologic, neurological, psychiatric, endocrine,&#xD;
             immunologic or dermatologic disease&#xD;
&#xD;
          9. No major surgery within 28 days prior to first dose&#xD;
&#xD;
         10. Suicidal tendency, disposition to seizures, state of confusion, clinically relevant&#xD;
             psychiatric diseases&#xD;
&#xD;
         11. Presence of out-of-range cardiac interval or ECG abnormalities&#xD;
&#xD;
         12. Maintenance therapy with any drug, or history of drug dependency or alcohol abuse&#xD;
&#xD;
         13. Any clinically significant illness in the previous 28 days before day 1 of study&#xD;
&#xD;
         14. Use of any enzyme-modifying drugs in the previous 28 days before day 1 of study&#xD;
&#xD;
         15. Use of any drugs known to induce or inhibit hepatic metabolism in the previous 28 days&#xD;
             before day 1 of study&#xD;
&#xD;
         16. Any history of tuberculosis and/or prophylaxis for tuberculosis&#xD;
&#xD;
         17. Positive urine screening of ethanol and/or drugs of abuse&#xD;
&#xD;
         18. Positive results to HIV, HBsAg or anti-Hepatitis C Virus tests&#xD;
&#xD;
         19. Females who are pregnant&#xD;
&#xD;
         20. Volunteers who took an Investigational Product or donated 50 mL or more of blood in&#xD;
             the previous 28 days before day 1 of this study&#xD;
&#xD;
         21. Donation of 500 mL or more of blood in the previous 56 days before day 1 of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Juretic</last_name>
    <role>Study Director</role>
    <affiliation>MethylGene Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food effect on MGCD265 bioavailability in healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

